Feasibility Study of Blood Biomarker Identification in Cervical Cancer (CLARITY)
Feasibility Study of Blood Biomarker Identification in Cervical Cancer: Performance of Cell-free DNA Versus Extracellular Vesicles
This study aims to explore whether a simple blood test can be used to help detect and monitor cervical cancer. The investigators are studying tiny fragments and particles found in blood, called cell-free DNA (cfDNA) and extracellular vesicles (EVs), to determine whether these can act as early warning signs (biomarkers) of cervical cancer.
Cell-free DNA (cfDNA) refers to tiny fragments of genetic material (DNA) that are naturally released from cells into the bloodstream when cells die or renew. Cell-free DNA circulates naturally in the blood. In people with cancer, some of the cfDNA originates from cancer cells; this component is called circulating tumour DNA (ctDNA). Analysis of cfDNA can detect signs of cancer, such as specific genetic changes or pieces of viral DNA, including human papillomavirus (HPV) DNA, without requiring removal of tissue from the cervix.
Extracellular vesicles (EVs) are very small "packages" released by cells into the blood and other body fluids. EVs carry messages between cells and contain important information such as proteins, fats, and genetic material, including RNA. In cancer, tumour cells release EVs that reflect tumour behaviour and activity. Analysis of EVs can provide information about cancer growth and response to treatment.
Together, cfDNA and EVs can act as tiny messengers or "fingerprints" of biological processes occurring inside the body. Analysis of cfDNA and EVs in blood samples may support the development of a simple, less invasive, more comfortable, and more accessible approach to detecting and monitoring cervical cancer compared with current screening and diagnostic methods. A blood test could also assist doctors in monitoring treatment response or detecting early signs of recurrence without requiring a surgical biopsy.
The expected outcomes of this study are to identify specific patterns or "signatures" in extracellular vesicles (EVs) and cell-free DNA (cfDNA) found in blood samples. These signatures could help to:
Detect cervical cancer earlier, before symptoms appear or the disease progresses.
Monitor treatment response in real time without the need for invasive tests. Predict whether cervical cancer might recur or spread after treatment. Support more personalised care by helping doctors select the most suitable treatment for each participant.
調査の概要
状態
条件
詳細な説明
This study is an open-label, prospective, experimental study of patients with cervical cancer. The primary aim is to evaluate the feasibility, clinical utility, and analytical performance of extracellular vesicles (EVs) and cell-free DNA (cfDNA) as minimally invasive, blood-based biomarkers for the early detection, treatment monitoring, and post-treatment surveillance of cervical cancer, with the potential to inform future screening and therapeutic strategies.
Cervical cancer continues to impose significant physical, emotional, and financial burdens on women worldwide. Despite advances in prevention and treatment, a critical need remains for more effective, non-invasive tools to support early detection, monitor treatment response, and guide clinical decision-making. As the field of cervical cancer diagnosis evolves, interest is growing in the use of blood-based biomarkers, particularly extracellular vesicles (EVs) and cell-free DNA (cfDNA), to improve patient care.
This study aims to evaluate the potential of EVs and cfDNA as minimally invasive biomarkers in the management of cervical cancer. Analysis of EVs and cfDNA is intended to provide deeper insights into the roles of these biomarkers in tumour development, progression, and intercellular communication. The anticipated outcomes include the identification of EV- and cfDNA-based signatures that can:
Facilitate earlier detection of cervical cancer. Enable real-time monitoring of treatment response. Predict recurrence and disease progression. Support the development of personalised therapeutic strategies.
By generating preliminary comparative data on the diagnostic accuracy of EVs and cfDNA, this study will provide a critical foundation for future large-scale investigations. The study is intended to contribute to the development of a novel, blood-based screening and monitoring tool that could enable earlier intervention and improve long-term outcomes.
A reliable, non-invasive test could also provide a more accessible and acceptable alternative to current cervical screening methods, particularly for women who face cultural, systemic, or personal barriers to participation. This is especially important for under-screened populations, including Aboriginal and Torres Strait Islander women and culturally diverse communities.
Ultimately, this research is expected to advance understanding of the biological role of EVs and cfDNA in cervical cancer pathogenesis and progression. The research supports the development of clinically effective, personalised diagnostic tools that may improve outcomes, reduce healthcare costs, contribute to Australia's national strategy to eliminate cervical cancer as a public health issue, and address persistent inequities in access to care.
Study Intervention
This prospective cohort study will enrol 100 patients with stage IA to IVB cervical cancer who are undergoing either primary surgical treatment, radiotherapy (RT), or chemoradiotherapy (CRT).
The study intervention involves the collection of approximately 40 mL of blood at baseline, following the initial diagnosis of cervical cancer, for the analysis of cell-free DNA, extracellular vesicles, and germline DNA. Additional blood samples of the same volume will be collected at two subsequent time points: at 8 weeks following surgery or completion of chemoradiotherapy (CRT), and at 6 months post-baseline.
In addition, quality-of-life questionnaires will be completed by participants at the following time points:
First time point: Baseline: For participants undergoing primary surgery, baseline is the date of surgery. For participants undergoing definitive radiotherapy or chemoradiotherapy, baseline is the date of the first radiation dose. Baseline assessments can be performed up to 30 days before the date of surgery or up to 30 days before the first radiation dose.
Second time point: Immediately after completion of radiotherapy or chemoradiotherapy (+14 days), or 8 weeks after surgery (±14 days).
Third time point: 6 months post-baseline (±14 days). Follow-up (24 Months)
Participant disease status will be recorded at 24 months (±30 days) through review of participants' medical records.
In accordance with current European Society for Medical Oncology (ESMO) guidelines, patients diagnosed with early-stage invasive cervical cancer, such as FIGO stage IA to IB2 and selected IIA1, typically undergo primary surgical treatment, including radical hysterectomy or simple hysterectomy. For these patients, the second blood collection will occur at 8 weeks post-surgery (±14 days).
For patients with locally advanced cervical cancer (LACC), for whom primary surgery is not recommended because of poor outcomes or increased morbidity associated with combined treatments, such as FIGO stages IB3, IIA2, IIB, and IIIA-IIIB, the preferred or definitive treatment is concurrent chemoradiotherapy (CRT) followed by internal radiation (brachytherapy). In these cases, the second blood sample will be collected at the end of treatment (+14 days).
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:Sara Baniahmadi
- 電話番号:+61 7 3346 5073
- メール:s.baniahmadi@uq.edu.au
研究連絡先のバックアップ
- 名前:Andreas Obermair
- 電話番号:+61 7 3346 5073
- メール:a.obermair@uq.edu.au
研究場所
-
-
Queensland
-
Brisbane、Queensland、オーストラリア、4029
- 募集
- Royal Brisbane and Women's Hospital
-
コンタクト:
- Sara Baniahmadi
- 電話番号:+61 7 3346 5073
- メール:s.baniahmadi@uq.edu.au
-
コンタクト:
- Jacqui Hall
- メール:Claritystudy@uq.edu.au
-
主任研究者:
- Kristen Moloney
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Females, over 18 years, with histologically confirmed squamous cell carcinoma or adenocarcinoma of the cervix (stage 1a to 4b)
- Undergo intensive primary surgical treatment, radiotherapy (RT) or chemoradiotherapy (CRT).
- Signed written informed consent
Exclusion Criteria:
- Unable to provide informed consent
- Serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator)
- Prior malignancies <5 years before inclusion, except for successfully treated keratinocyte skin cancers, or ductal carcinoma in situ.
研究計画
研究はどのように設計されていますか?
デザインの詳細
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Patients with Cervical Cancer
Patients with FIGO stage IA-IVB cervical cancer undergoing standard-of-care primary surgery, radiotherapy, or chemoradiotherapy.
Treatment is determined by the participant's treating clinical team and is not assigned by the study protocol.
Participants will undergo serial blood collection for cfDNA and extracellular vesicle analyses, complete patient-reported outcome and quality-of-life questionnaires, and have disease status assessed through medical record review.
Archival tumour tissue obtained during routine diagnostic biopsy or surgery will also be retrieved where available for translational analyses.
|
Approximately 40 mL of blood will be collected at baseline, approximately 8 weeks (±14 days) after surgery or within 14 days following completion of radiotherapy/chemoradiotherapy, and 6 months (±14 days) post-baseline.
Blood samples will be processed for isolation and analysis of cell-free DNA (cfDNA), extracellular vesicles (EVs), and germline DNA.
他の名前:
Blood-derived cell-free DNA (cfDNA) and extracellular vesicles (EVs) will be isolated and characterised using prespecified laboratory methods.
cfDNA will be quantified, quality assessed, and may undergo sequencing.
EVs will be characterised using methods including nanoparticle tracking analysis, transmission electron microscopy, western blotting, proteomics, and miRNA sequencing.
Biomarker profiles will be evaluated in relation to disease stage, treatment response, and disease outcomes.
Participants will complete patient-reported outcome and quality-of-life questionnaires at baseline, approximately 8 weeks after surgery or completion of radiotherapy/chemoradiotherapy, and 6 months post-baseline.
Assessments include the FACT-Cx, EQ-5D-5L, and self-reported lower-extremity lymphoedema questionnaires.
Formalin-fixed paraffin-embedded (FFPE) tumour tissue obtained during routine diagnostic biopsy or surgery will be retrieved from pathology laboratories where available.
No research-specific tumour biopsy or surgery will be performed.
Tumour tissue may undergo DNA extraction and sequencing for comparison with blood-derived DNA and other prespecified translational analyses.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Proportion of participants with successful blood collection and analysable cfDNA and EVs
時間枠:Baseline; approximately 8 weeks (±14 days) after surgery or within 14 days following completion of radiotherapy/chemoradiotherapy; and 6 months (±14 days) post-baseline.
|
Percentage of enrolled participants for whom blood is successfully collected and both cell-free DNA (cfDNA) and extracellular vesicles (EVs) are successfully isolated and meet prespecified laboratory quality-control criteria for the planned downstream analyses.
Feasibility will be assessed at each of the three scheduled blood-collection time points.
|
Baseline; approximately 8 weeks (±14 days) after surgery or within 14 days following completion of radiotherapy/chemoradiotherapy; and 6 months (±14 days) post-baseline.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Proportion of eligible patients who consent to participate
時間枠:At study screening/enrolment.
|
Percentage of eligible patients with cervical cancer who provide informed consent and enrol in the study among all eligible patients approached for participation.
|
At study screening/enrolment.
|
|
Proportion of cfDNA samples meeting prespecified analytical quality criteria
時間枠:Baseline; approximately 8 weeks (±14 days) after surgery or within 14 days following completion of radiotherapy/chemoradiotherapy; and 6 months (±14 days) post-baseline.
|
Percentage of collected plasma samples from which cell-free DNA (cfDNA) is successfully extracted and meets prespecified quality-control criteria for downstream analysis.
cfDNA will be quantified and quality assessed, including assessment of yield, integrity, and suitability for planned molecular analyses and/or sequencing.
|
Baseline; approximately 8 weeks (±14 days) after surgery or within 14 days following completion of radiotherapy/chemoradiotherapy; and 6 months (±14 days) post-baseline.
|
|
Proportion of extracellular vesicle samples meeting prespecified analytical quality criteria
時間枠:Baseline; approximately 8 weeks (±14 days) after surgery or within 14 days following completion of radiotherapy/chemoradiotherapy; and 6 months (±14 days) post-baseline.
|
Percentage of collected plasma/serum samples from which extracellular vesicles (EVs) are successfully isolated and meet prespecified quality-control criteria for downstream analysis.
EV quantity and characteristics will be evaluated using methods including nanoparticle tracking analysis, transmission electron microscopy, and assessment of positive and negative EV markers by western blotting.
|
Baseline; approximately 8 weeks (±14 days) after surgery or within 14 days following completion of radiotherapy/chemoradiotherapy; and 6 months (±14 days) post-baseline.
|
|
Association between baseline cfDNA profiles and cervical cancer stage
時間枠:Baseline
|
Association between baseline cell-free DNA (cfDNA) characteristics and cervical cancer stage (FIGO stage IA-IVB).
Prespecified cfDNA measures and/or molecular signatures obtained from plasma will be evaluated for differences across disease stages.
Where applicable, tumour tissue and germline DNA sequencing data will be used as reference controls.
|
Baseline
|
|
Association between baseline extracellular vesicle profiles and cervical cancer stage
時間枠:Baseline
|
Association between baseline extracellular vesicle (EV) characteristics and cervical cancer stage (FIGO stage IA-IVB).
Prespecified EV characteristics, including EV quantity and molecular cargo such as proteins and miRNAs, will be evaluated for differences across disease stages.
|
Baseline
|
|
Association between changes in cfDNA biomarkers and response to radiotherapy or chemoradiotherapy
時間枠:From baseline to the post-treatment assessment, within 14 days following completion of radiotherapy or chemoradiotherapy.
|
Association between changes in cell-free DNA (cfDNA) biomarkers from baseline to the post-treatment assessment and treatment response among participants receiving radiotherapy or chemoradiotherapy.
Treatment response will be determined according to the prespecified clinical and/or radiological response criteria defined in the protocol or statistical analysis plan.
|
From baseline to the post-treatment assessment, within 14 days following completion of radiotherapy or chemoradiotherapy.
|
|
Association between changes in extracellular vesicle biomarkers and response to radiotherapy or chemoradiotherapy
時間枠:From baseline to the post-treatment assessment, within 14 days following completion of radiotherapy or chemoradiotherapy.
|
Association between changes in extracellular vesicle (EV) characteristics from baseline to the post-treatment assessment and treatment response among participants receiving radiotherapy or chemoradiotherapy.
EV characteristics may include quantity and prespecified molecular profiles, including protein and miRNA profiles.
Treatment response will be determined using the prespecified clinical and/or radiological response criteria.
|
From baseline to the post-treatment assessment, within 14 days following completion of radiotherapy or chemoradiotherapy.
|
|
Association between cfDNA and EV biomarkers and 24-month disease outcome
時間枠:From baseline through 24 months (±30 days).
|
Association of baseline and longitudinal cell-free DNA (cfDNA) and extracellular vesicle (EV) biomarker profiles with disease status at 24 months, including recurrence or disease progression as defined in the protocol.
Disease status will be determined through review of participants' medical records.
|
From baseline through 24 months (±30 days).
|
|
Completion rate of patient-reported outcome and quality-of-life questionnaires
時間枠:Baseline; approximately 8 weeks (±14 days) after surgery or within 14 days following completion of radiotherapy/chemoradiotherapy; and 6 months (±14 days) post-baseline.
|
Percentage of participants who complete the scheduled patient-reported outcome measure (PROM) and quality-of-life (QoL) questionnaires at each assessment time point.
Questionnaires include the Functional Assessment of Cancer Therapy-Cervix (FACT-Cx), EQ-5D-5L, and lower-extremity lymphoedema questionnaires.
|
Baseline; approximately 8 weeks (±14 days) after surgery or within 14 days following completion of radiotherapy/chemoradiotherapy; and 6 months (±14 days) post-baseline.
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- 泌尿生殖器疾患
- 生殖器疾患
- 泌尿生殖器腫瘍
- 部位別新生物
- 新生物
- 女性の泌尿生殖器疾患
- 女性の泌尿生殖器疾患と妊娠合併症
- 子宮の病気
- 生殖器疾患、女性
- 性器腫瘍、女性
- 子宮頸部疾患
- 子宮腫瘍
- 子宮頸部腫瘍
- 保健サービス管理
- ヘルスケアの質、アクセス、評価
- 調査手法
- 疫学的方法
- 核酸
- 核酸、ヌクレオチド、およびヌクレオシド
- データ収集
- ヘルスケア評価メカニズム
- ヘルスケアの質
- 公衆衛生
- 環境と公衆衛生
- ヘルスケアの経済学と組織
- 結果の評価、ヘルスケア
- 結果とプロセス評価、ヘルスケア
- 調査とアンケート
- 健康計画
- ヘルスケア調査
- 医療サービスの研究
- 患者の転帰評価
- 無細胞核酸
- 患者はアウトカム測定を報告しました
その他の研究ID番号
- Clarity
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。